Stock Financial Ratios, Dividends, Split History

STZ / Constellation Brands, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)39,160.86
Enterprise Value ($M)48,532.76
Book Value ($M)8,046.10
Book Value / Share47.88
Price / Book4.87
NCAV ($M)-9,002.00
NCAV / Share-53.56
Price / NCAV-4.34
Share Statistics
Number Of Classes Of Common Stock With Material Number Of Shares Outstanding 2
Common Shares Outstanding2 23,326,443
Common Shares Outstanding3 7,088
Common Shares Outstanding 168,057,947
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.13
Return on Assets (ROA)0.12
Return on Equity (ROE)0.34
Balance Sheet (mrq) ($M)
Quick Ratio0.71
Current Ratio1.79
Income Statement (mra) ($M)
Sales Revenue Goods Net8,326,800,000.00
Operating Income2,284.50
Net Income2,318.90
Cash Flow Statement (mra) ($M)
Cash From Operations1,931.40
Cash from Investing-1,423.10
Cash from Financing1,931.40
Identifiers and Descriptors
Central Index Key (CIK)16918
Related CUSIPS
21036P907 21036P958 21036P207 21036P957 021036P10 21036P908
Industry Groups
SIC 208 - Beverages

Split History

Stock splits are used by Constellation Brands, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Cramer Remix: If the economy slows down, own FANG

2018-06-14 cnbc
The entire entertainment sector is readjusting after AT&T got legal clearance to buy Time Warner and Comcast topped Disney's bid for a key portion of Twenty-First Century Fox's assets, CNBC's Jim Cramer said Thursday. (139-0)

Cramer's lightning round: Skechers in the 'penalty box' until earnings

2018-06-14 cnbc
Skechers USA: "The stock had been a red-hot momentum stock not unlike Deckers and Deckers delivered and Skechers didn't and that's why the stock came down, so it's in the penalty box until we see the next quarter." (46-0)

Is Molson Coors Brewing Co Stock Set to Rebound 20%?

2018-06-12 investorplace
Investors in Molson Coors Brewing Co (NYSE:TAP) have to be disappointed so far this year. TAP stock is down more than 22% so far in 2018 and more than 27% over the past 12 months. This is compared to the 4.25% year-to-date gain in the SPDR S&P 500 ETF Trust (NYSEARCA:SPY). While Molson now yields 2.6%, investors have to be asking themselves if it’s time to pass on this brew and look for a more refreshing stock. (29-0)

Vina Concha y Toro: 135 Years Of Success, 135 To Come

2018-06-12 seekingalpha
Concha y Toro is a built to last firm with 52% insider ownership and 135 years of success. (12-0)

Brewers see future in high tech, weak beer, cannabis brews

2018-06-08 reuters
BRUSSELS, June 8 (Reuters) - A ‘smart’ bottle opener, weak and alcohol-free ales and lagers and cannabis brews - all visions of the future of beer offered at a brewing convention in Brussels this week. (33-0)

CUSIP: 21036P108